Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

18.0K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
18.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study protocol: double-blind, randomized, prospective, placebo controlled parallel group phase II study to investigate the effect of glycerol phenylbutyrate (GPB) on neurofilament light chain (NfL) levels in patients with corticobasal syndrome (CBS).

Neurological research and practice·2026
Same author

Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Temporal Patterns of Fever Onset as an Indicator of Etiology in Intracerebral Hemorrhage.

Neurology international·2026
Same author

Brain connectome reorganization across the lifespan in relapsing-remitting multiple sclerosis.

European journal of radiology·2026
Same author

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Large-scale proteomics across neurological disorders uncovers biomarker panel and targets in multiple sclerosis.

Cell·2026

Related Experiment Video

Updated: Mar 27, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K

B cell-directed therapies in multiple sclerosis.

Christiane Gasperi1, Olaf Stüve1,2, Bernhard Hemmer1,3

  • 1Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675 München, Germany.

Neurodegenerative Disease Management
|January 20, 2016
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) is a neurological disease impacting young adults. B cell therapies show promise in reducing relapses and slowing disability progression in relapsing-remitting MS.

More Related Videos

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.4K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Related Experiment Videos

Last Updated: Mar 27, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.4K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Area of Science:

  • Neurology
  • Immunology
  • Neuroimmunology

Background:

  • Multiple sclerosis (MS) is a chronic, inflammatory central nervous system (CNS) disease causing demyelination and neurodegeneration.
  • It represents the primary cause of acquired, nontraumatic neurological disability in young adults.
  • While treatments exist for relapsing-remitting MS (RRMS), ongoing research seeks improved therapeutic strategies.

Purpose of the Study:

  • To review the role of B cells in the pathogenesis of multiple sclerosis.
  • To discuss current and emerging therapeutic strategies targeting B cells in MS.
  • To evaluate the efficacy of B cell-depleting therapies in RRMS.

Main Methods:

  • Review of Phase II and Phase III clinical trials involving CD20-positive B cell-targeting monoclonal antibodies (rituximab, ocrelizumab, ofatumumab).
  • Analysis of MRI-based data to assess disease-ameliorating effects.
  • Discussion of the immunological mechanisms underlying B cell involvement in MS.

Main Results:

  • Consistent evidence supports the disease-ameliorating effects of B cell-depleting therapies in RRMS.
  • Monoclonal antibodies targeting CD20-positive B cells have demonstrated efficacy in reducing relapses and delaying disability progression.
  • These findings highlight the significant role of B cells in MS pathogenesis.

Conclusions:

  • B cell-depleting therapies represent a significant advancement in managing relapsing-remitting MS.
  • Targeting B cells offers a viable therapeutic avenue for reducing MS-related disability.
  • Future research should continue to explore and refine B cell-targeted strategies for MS treatment.